Remove BMI Remove Heart Failure Remove Preserved Ejection Fraction
article thumbnail

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER

European Journal of Heart Failure

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased.

article thumbnail

University Hospitals Researcher Develops New Score System to Better Screen and Treat HFpEF Heart Failure Patients

DAIC

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

article thumbnail

Adiposity, fat-free mass and incident heart failure in 500 000 individuals

Open Heart

Background and aims The independent role of body fat distribution and fat-free mass in heart failure (HF) risk is unclear. Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95% CI 1.32 years, 44% male) from the UK Biobank. to 2.07).

article thumbnail

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Circulation

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks.

article thumbnail

Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity

European Journal of Heart Failure

BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction.

Obesity 40
article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] to 25 kg/m2) and underweight (BMI less than 18.5 kg/m2) or severe obesity (BMI greater than 40 kg/m2).

Obesity 52